Video

Dr. Orellana-Noia on the Treatment of High-Risk and Vulnerable Patient Populations with DLBCL

Victor M. Orellana-Noia, MD, discusses the treatment of high-risk and vulnerable patients with diffuse large B-cell lymphoma.

Victor M. Orellana-Noia, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, discusses the treatment of high-risk and vulnerable patients with diffuse large B-cell lymphoma (DLBCL).

Although there are data emerging from many phase 2 and 3 trials in DLBCL and other hematologic malignancies, high-risk and vulnerable patient populations are often excluded from these trials, Orellana-Noia adds. The younger, more fit patients enrolled in these trials generally do not present with central nervous system disease, HIV, prior solid organ transplant, and more, Orellana-Noia explains.

Investigators must make efforts to make clinical trial eligibility more inclusive to evaluate emerging therapies in patients who have higher-risk disease, Orellana-Noia concludes.

Related Videos
Deena Mary Atieh Graham, MD
 Rupesh Rajesh Kotecha, MD
David A. Braun, MD, PhD
Francine Foss, MD
Daniel E. Haggstrom, MD
Ami Umesh Badami, MD
Kenneth Shain, MD, PhD
Piotr Rutkowski, MD
Manali Kamdar, MD, of University of Colorado Anschutz School of Medicine
Janaki Neela Sharma, MD, assistant professor, clinical medicine, Genitourinary Medical Oncology, University of Miami Health Systems